Human procalcitonin and the preparation and use thereof

Details Human procalcitonin and the preparation and use thereof Human procalcitonin and the preparation and use thereof

2008-03-04

2008-03-04

Mosher, Mary E. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S188000, C436S501000, C530S307000, C530S350000, C930S060000

Reexamination Certificate

active

11055622

ABSTRACT:
The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is inserted into a vector; a host organism is transformed with this gene-containing vector; and the polypeptide expressed by the host organism is isolated. Furthermore the use of the polypeptides according to the invention, in particular as medicaments and diagnostic agents is described.

REFERENCES:
patent: 3057782 (1962-10-01), Lindner et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 5340716 (1994-08-01), Ullman et al.
patent: 5545834 (1996-08-01), Singh et al.
patent: 5639617 (1997-06-01), Bohuon
patent: 5740800 (1998-04-01), Hendrickson et al.
patent: 5915240 (1999-06-01), Karpf
patent: 5993811 (1999-11-01), Becker et al.
patent: 1155134 (1958-06-01), None
patent: 198 47 690 (2000-04-01), None
patent: 199 03 336 (2000-08-01), None
patent: 0 080 614 (1982-11-01), None
patent: 0 227 054 (1986-12-01), None
patent: 0 246 446 (1987-04-01), None
patent: 0 411 945 (1990-08-01), None
patent: 0 515 194 (1992-05-01), None
patent: 0 656 121 (1993-08-01), None
patent: 0 997 735 (1999-09-01), None
patent: 1 026 506 (2000-01-01), None
patent: 1 111 050 (2001-06-01), None
patent: WO 98/33524 (1988-01-01), None
patent: WO 95/06877 (1995-03-01), None
patent: WO 95/25172 (1995-09-01), None
Dandona, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. Dec. 1994;79(6):1605-8.
Van Dyke, et al. Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain. Gene. 1992, 111(1):99-104.
S. Wrenger et al., “Amino-terminal Truncation of Procalcitonin, a Marker for Systemic Bacterial Infections, by Dipeptidyl Peptidase IV (DP IV), 2000” Federation of European Biochemical Societies Letters 466, No. 1, (2000), pp. 155-159.
Xiao-Quing Liu et al., “A Novel Method for Increasing Production of Mature Proteins in the Periplasm ofEscherichia coli,” Protein Science (1999), vol. 8, 1999, Cambridge University Press, The Protein Society, pp. 2085-2089.
Rainer Fischer et al., “Molecular Farming of Recombinant Antibodies in Plants,” Biol. Chem., vol. 380, Jul./Aug. 1999, pp. 825-839.
Eric S. Nylen, et al. , “Mortality is Increased by Procalcitonin and Decreased by an Antiserum Reactive to Procalcitonin in Experimental Sepsis,” Crit. Care Med. 1998, vol. 26, No. 6, pp. 1001-1006.
W. Karzai et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections,” Infection, 6, A Journal of Infectious Disease—Clinical Study and Treatment, vol. 25, 1997, pp. 329-334.
Edwin F. Ullman et al., “Luminescent Oxygen Channeling Assay (LOCI™): Sensitive, Broadly Applicable Homogeneous Immunoassay Method,” Clinical Chemistry, vol. 42, No. 9, 1996, pp. 1518.
Edwin F. Ullman et al., “Luminescent Oxygen Channeling Immunoassay: Measurement of Particle Binding Kinetics by Chemiluminescence,” Proc. Natl. Acad. Sci, USA, vol. 91, 1994, pp. 5426.
Gérard Mathis, “Rare Earth Cryptates and Homogeneous Fluoroimmunoassays with Human Sera,” Clin. Chem., vol. 39, No. 9, 1993, pp. 1953.
Andrew Hiatt et al., “Assembly of Antibodies and Mutagenized Variants in Transgenic Plants and Plant Cell Cultures,” Genetic Engineering, vol. 14, 1992, pp. 49.
James W. Larrick et al., “Recombinant Antibodies,” Review, vol. 2, 1991, pp. 172.
J. Michael Conlon et al., “Structural Characterization of a High Molecular-mass Form of Calcitonin [procalcitonin-(60-116)-peptide] and Its Corresponding N-terminal Flanking Peptide [procalcitonin-(1-57)-peptide] in a Human Medullary Thyroid Carcinoma,” Biochem., vol. 256, 1988, pp. 245-250.
Pascale P. Ghillani et al., “Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases,” Cancer Research, vol. 49, 1989, pp. 6845.
Pascale Ghillani et al., “Monoclonal Antipeptide Antipeptide Antibodies As Tools To Dissect Closely Related Gene Products,” The Journal of Immunology, vol. 141, 1988, pp. 3156-3163.
Antibodies—A Laboratory Manual—1988.
M. Philip Bailey et al., “On the Use of Fluorescent Labels in Immunoassay,” Journal of Pharmaceutical & Biomedical Analysis, vol. 5, 1987, pp. 649-658.
Kazuaki Kitano et al., “Production of Human Monoclonal Antibodies by Heterohybridomas,” Appl Microbiol Biotechnol, vol. 24, 1986, pp. 282-286.
Sidney Udenfriend et al., “Scintillation Proximity Radioimmunoassay Utilizing 125I-labeled Ligands,” Proc. Natl. Acad. Sci, USA, vol. 82, 1985, pp. 8672-7676.
Le Moullec et al., “The Complete Sequence of Human Preprocalcitonin,” FEBS Lett., vol. 167, 1984, pp. 93-97.
R.C. Boguslaski et al., “Homogeneous Immunoassays,” Applied Biochemistry and Biotechnology, vol. 7, 1982, pp. 401-414.
Snider et al., Journal of Investigative Medicine, vol. 45, 1997, pp. 552-560.

Affiliated with

Also associated with

Rating

Human procalcitonin and the preparation and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human procalcitonin and the preparation and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human procalcitonin and the preparation and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3932434